Gentian Diagnostics ASA

Prospectus • Jun 24, 2021

Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs

Gentian Diagnostics ASA – Approval and publication of prospectus, and transfer of listing from Euronext Growth (Oslo) to Oslo Børs

Moss, 24 June 2021

Reference is made to the announcement made by Gentian Diagnostics ASA (the "Company") on 7 May 2021 where it was announced that the Company had submitted an application for admission to trading on Oslo Børs (the "Listing") by transfer of its current admission to trading on Euronext Growth Oslo. The application was approved on 23 June 2021.

The first day of trading of the Company's shares on Oslo Børs’ main list is expected to be on 25 June 2021. Consequently, the last day of trading of the Company's shares on Euronext Growth Oslo is expected to be today, 24 June 2021.

The Company has prepared a prospectus in connection with the Listing (the "Prospectus"), which has been approved by the Norwegian Financial Supervisory Authority. The Prospectus is available at:

www.gentian.com/investor-relations-stock-information/key-information-investors/

Hard copies of the Prospectus may be obtained free of charge at the Company's registered business address Bjørnåsveien 5, 1596 Moss, Norway (subject to prevailing restrictions due to the Covid-19 pandemic).

AGP Advokater AS has acted as legal counsel to the Company in connection with the Listing and Advokatfirmaet Selmer AS and Moore Consulting AS have acted as due diligence advisors.

For further information please contact:

Hilja Ibert CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242

Njaal Kind CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525